Trial Profile
Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2020
Price :
$35
*
At a glance
- Drugs Omidenepag isopropyl (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Therapeutic Use
- 11 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2018 New trial record